BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 27038366)

  • 1. Differences in health-related quality of life between European and Asian patients with hepatocellular carcinoma.
    Chie WC; Blazeby JM; Hsiao CF; Chiu HC; Poon RT; Mikoshiba N; Al-Kadhim G; Heaton N; Calara J; Collins P; Caddick K; Costantini A; Vilgrain V;
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e304-e311. PubMed ID: 27038366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma - clinical application of health-related quality-of-life data.
    Li L; Mo FK; Chan SL; Hui EP; Tang NS; Koh J; Leung LK; Poon AN; Hui J; Chu CM; Lee KF; Ma BB; Lai PB; Chan AT; Yu SC; Yeo W
    BMC Cancer; 2017 Jan; 17(1):8. PubMed ID: 28052758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Status of inflammation in relation to health related quality of life in hepatocellular carcinoma patients.
    Li L; Chan SL; Mo F; Hui EP; Koh J; Chan AK; Tang NL; Chu CM; Hui J; Lee KF; Yu S; Yeo W
    Qual Life Res; 2019 Sep; 28(9):2597-2607. PubMed ID: 31037590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. International cross-cultural field validation of an European Organization for Research and Treatment of Cancer questionnaire module for patients with primary liver cancer, the European Organization for Research and Treatment of Cancer quality-of-life questionnaire HCC18.
    Chie WC; Blazeby JM; Hsiao CF; Chiu HC; Poon RT; Mikoshiba N; Al-Kadhimi G; Heaton N; Calara J; Collins P; Caddick K; Costantini A; Vilgrain V; Trinquart L; Chiang C;
    Hepatology; 2012 Apr; 55(4):1122-9. PubMed ID: 22105642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of the Japanese version of the EORTC hepatocellular carcinoma-specific quality of life questionnaire module (QLQ-HCC18).
    Mikoshiba N; Tateishi R; Tanaka M; Sakai T; Blazeby JM; Kokudo N; Koike K; Kazuma K
    Health Qual Life Outcomes; 2012 May; 10():58. PubMed ID: 22651810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association of liver function and quality of life of patients with liver cancer.
    Li L; Mo F; Hui EP; Chan SL; Koh J; Tang NLS; Yu SCH; Yeo W
    BMC Gastroenterol; 2019 May; 19(1):66. PubMed ID: 31046687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychometric validation of the EORTC QLQ-HCC18 in patients with previously treated unresectable hepatocellular carcinoma.
    Serrano D; Podger L; Barnes G; Song J; Tang B
    Qual Life Res; 2022 Mar; 31(3):937-950. PubMed ID: 34518988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a questionnaire module to supplement the EORTC QLQ-C30 to assess quality of life in patients with hepatocellular carcinoma, the EORTC QLQ-HCC18.
    Blazeby JM; Currie E; Zee BC; Chie WC; Poon RT; Garden OJ;
    Eur J Cancer; 2004 Nov; 40(16):2439-44. PubMed ID: 15519517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depressive symptoms after treatment in hepatocellular carcinoma survivors: prevalence, determinants, and impact on health-related quality of life.
    Mikoshiba N; Miyashita M; Sakai T; Tateishi R; Koike K
    Psychooncology; 2013 Oct; 22(10):2347-53. PubMed ID: 23686523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and Validation of the Simplified Chinese Version of EORTC QLQ-HCC18 for Patients with Hepatocellular Carcinoma.
    Yang Z; Wan C; Li W; Cun Y; Meng Q; Ding Y; Chen P
    Cancer Invest; 2015; 33(8):340-6. PubMed ID: 26046473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlations of health-related quality of life with serum inflammatory indicators IL-8 and mIBI in patients with hepatocellular carcinoma.
    Li L; Chan SL; Mo F; Hui EP; Koh J; Chan AKC; Tang NLS; Lee KF; Lai PBS; Yu SCH; Yeo W
    Cancer Manag Res; 2019; 11():2719-2727. PubMed ID: 31040713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
    Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
    Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Prospective Evaluation of the Reliability and Utility of Quality of Life Measures in Patients With Hepatocellular Carcinoma.
    Kim GA; Kim HI; Chang S; An J; Lee D; Lee HC; Han S; Shim JH
    Am J Clin Oncol; 2019 Jul; 42(7):555-563. PubMed ID: 31135382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Normative data for the EORTC QLQ-C30 from the Austrian general population.
    Lehmann J; Giesinger JM; Nolte S; Sztankay M; Wintner LM; Liegl G; Rose M; Holzner B;
    Health Qual Life Outcomes; 2020 Aug; 18(1):275. PubMed ID: 32787854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240.
    Ryoo BY; Merle P; Kulkarni AS; Cheng AL; Bouattour M; Lim HY; Breder V; Edeline J; Chao Y; Ogasawara S; Yau T; Garrido M; Chan SL; Daniele B; Norquist JM; Chen E; Siegel AB; Zhu AX; Finn RS; Kudo M
    Cancer; 2021 Mar; 127(6):865-874. PubMed ID: 33231873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
    Vogel A; Qin S; Kudo M; Su Y; Hudgens S; Yamashita T; Yoon JH; Fartoux L; Simon K; López C; Sung M; Mody K; Ohtsuka T; Tamai T; Bennett L; Meier G; Breder V
    Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):649-658. PubMed ID: 34087115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Summary scores captured changes in subjects' QoL as measured by the multiple scales of the EORTC QLQ-C30.
    Phillips R; Gandhi M; Cheung YB; Findlay MP; Win KM; Hai HH; Yang JM; Lobo RR; Soo KC; Chow PK
    J Clin Epidemiol; 2015 Aug; 68(8):895-902. PubMed ID: 25843232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The EORTC Quality of Life Questionnaire for cancer patients (QLQ-C30): Australian general population reference values.
    Mercieca-Bebber R; Costa DS; Norman R; Janda M; Smith DP; Grimison P; Gamper EM; King MT
    Med J Aust; 2019 Jun; 210(11):499-506. PubMed ID: 31155722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role functioning is associated with survival in patients with hepatocellular carcinoma.
    Meier A; Yopp A; Mok H; Kandunoori P; Tiro J; Singal AG
    Qual Life Res; 2015 Jul; 24(7):1669-75. PubMed ID: 25502092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. General Spanish population normative data analysis for the EORTC QLQ-C30 by sex, age, and health condition.
    Arraras JI; Nolte S; Liegl G; Rose M; Manterola A; Illarramendi JJ; Zarandona U; Rico M; Teiejria L; Asin G; Hernandez I; Barrado M; Vera R; Efficace F; Giesinger JM;
    Health Qual Life Outcomes; 2021 Aug; 19(1):208. PubMed ID: 34461909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.